The overexpression of the HER2 protein largely contributes to tumor progression and metastasis, and several studies have investigated the therapeutic potential of HER2-CAR-NK cell-based therapies in breast tumors, which induce the selective elimination of tumor cells in orthotopic breast carcinoma xenografts [19,29]. This evidence concerns the gene ERBB2 and neoplasm.